Fennec Pharmaceuticals markets Pedmark to reduce cisplatin-induced ototoxicity in pediatric patients but faces challenges in adoption. FENC has missed financial projections, with revenues below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback